Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Lymphoma, Follicular 12Lymphoma, Large B-Cell, Diffuse 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Mantle-Cell 8Leukemia, Lymphocytic, Chronic, B-Cell 8Burkitt Lymphoma 8Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Hematologic Neoplasms 3Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Hodgkin Disease 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasm, Residual 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, AIDS-Related 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphoid 1Histiocytosis, Langerhans-Cell 1HIV Infections 1Composite Lymphoma 1

Interventions

Rituximab 49fludarabine phosphate 32Cyclophosphamide 30Whole-Body Irradiation 26Peripheral Blood Stem Cell Transplantation 25Mycophenolic Acid 24Tacrolimus 19Cyclosporine 16Dexamethasone 13Busulfan 13ibrutinib 12Sirolimus 12Bortezomib 11Antilymphocyte Serum 11Melphalan 10Etoposide 10Calcium Dobesilate 10Methotrexate 8Lenalidomide 8Cyclosporins 8idelalisib 7Everolimus 6Indium 5Filgrastim 5thymoglobulin 4ibritumomab tiuxetan 4carfilzomib 4Vincristine 4Prednisone 4In Situ Hybridization, Fluorescence 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Waldenstrom Macroglobulinemia × CT-P10 × Clear all
NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Active not recruiting
33 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
9 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03269552 2020-01-18

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

University of Washington

Phase 2 Terminated
4 enrolled 12 charts
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡